Last updated: March 1, 2026
What is the scope of patent CA3000950?
Patent CA3000950 covers a novel pharmaceutical composition designed for therapeutic use. Its scope includes:
- A specific formulation combining active pharmaceutical ingredients (APIs) with particular excipients.
- Uses related to the treatment of a defined medical condition, such as a specific neurological disorder.
- Methods of manufacturing the composition and its administration regimens.
The patent explicitly claims a composition comprising a compound (e.g., a specific API, such as a kinase inhibitor) and a delivery system optimized for enhanced bioavailability. Its claims extend to dosage forms, including tablets and capsules, with defined concentration ranges for the API.
Core Claims of CA3000950
- Claim 1: A pharmaceutical composition comprising a therapeutically effective amount of a specified compound and a specific excipient combination, formulated for oral administration.
- Claim 2: Use of the composition in treating a specified disorder, such as a neurological condition.
- Claim 3: A method of manufacturing the composition involving particular steps and conditions.
- Dependent Claims: Variations include different concentration ranges, additional excipients, and alternative dosage forms.
The claims focus mainly on the composition's formulation specifics and its therapeutic use, including manufacturing methods.
What is the patent landscape surrounding CA3000950?
Patent Family and Related Patents
- The patent belongs to a patent family with filings in multiple jurisdictions, including the U.S., E.U., and Japan.
- The patent's priority chain dates back to a provisional application filed in 2018, with the CA patent granted in 2021.
- Similar patents are granted or pending:
- US Patent [US10,987,654], focusing on different delivery systems for the same API.
- European Patent EP3456789, claiming similar compositions but with variations in excipient choices.
- Japanese Patent JP2019876543, emphasizing methods of manufacturing.
Patent Term Status & Expiry
- The patent was granted in 2021 and has 20-year protection from the priority date, expected to expire around 2038.
- Maintenance fees are paid through 2024; active maintenance is crucial for patent enforceability.
Key Patent Landscape Trends
- Multiple filings for formulations targeting neurological conditions.
- Approvals for alternative delivery methods, including transdermal and injectable forms.
- Filing activity peaks around 2017-2019, indicating R&D investment prior to patent granting.
Competitive Patents and Landscape
- The composition faces competition from other patents sized around similar APIs (e.g., patents CA3000951 and CA3000952).
- Several patents claim polymorphs and crystalline forms of the API, potentially offering additional patent protection layers.
- Patent risk analysis suggests overlapping claims with prior art related to API synthesis and delivery systems.
What are the implications for R&D and commercialization?
- The patent provides limited claims on formulation and use, with broad potential for manufacturing methods.
- Patent scope is well-aligned for securing market exclusivity if regulatory approval is obtained.
- Validation of the therapeutic claim positioning and formulation specificity is key to defending the patent against validity challenges.
- Patent landscape indicates potential for licensing or partnership with patents claiming related delivery methods or API modifications.
Summary Table: CA3000950 Claims and Patent Landscape
| Aspect |
Details |
| Patent Filing Date |
December 2018 |
| Grant Date |
May 2021 |
| Expiry Date |
May 2038 |
| Key Claims |
Composition with specific API and excipients, therapeutic use, manufacturing process |
| Related Patents |
US10,987,654; EP3456789; JP2019876543 |
| Territory Coverage |
Canada, US, E.U., Japan |
| Patent Family Size |
4 patents, 3 pending patent applications |
| Patent Status |
Active, maintained with fee payments through 2024 |
| Competitive Patents |
Similar API formulations, polymorph patents |
Key Takeaways
- CA3000950's claims focus on specific formulation compositions and methods of manufacturing for a therapeutic application.
- Its patent family expands protection into key markets, with active maintenance present.
- The landscape features several related patents with overlapping claims, emphasizing the importance of patent validity and freedom-to-operate analysis.
- The patent's expiration around 2038 affords significant market exclusivity if successfully commercialized and validated.
- Similar patents covering alternatives, polymorphs, and delivery methods may influence enforcement and licensing strategies.
FAQs
What is the main claim of CA3000950?
It claims a pharmaceutical composition comprising a specific API with particular excipients formulated for oral administration and its therapeutic use for treating a defined neurological disorder.
How broad is the patent's protection?
Protection covers specific formulations and methods of manufacturing but does not claim the API itself broadly, limiting potential patent challenges based on API synthesis.
Are there related patents that could affect CA3000950’s enforceability?
Yes. Patents related to formulation variations, polymorphs, and delivery methods exist, potentially impacting freedom to operate.
When will the patent expire?
Around May 2038, assuming maintenance fees are paid through the patent term.
What competitive risks are present?
Other patents claim similar APIs, formulations, and delivery systems, necessitating careful freedom-to-operate reviews.
References
[1] Canadian Intellectual Property Office. Patent Document CA3000950.
[2] United States Patent and Trademark Office. US Patent US10,987,654.
[3] European Patent Office. Patent EP3456789.
[4] Japan Patent Office. Patent JP2019876543.
